HKUST and Pangu BioPharma (an aTyr Pharma Subsidiary) recognized for pioneering work leading to new investigational therapeutic for lung disease

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, recognized the collaboration between its Hong Kong subsidiary, Pangu BioPharma (Pangu), and HKUST for contributions leading to the discovery of ATYR1923, which is currently being evaluated in patients with pulmonary sarcoidosis.